Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Brand-name drug

Eliquis price, strengths & recalls

Brand of apixaban (generic)

Pharmacies pay $165.64 for 30 tablets of Eliquis 5 mg tablet this week, and from $165.37 to $407.52 across its 3 priced strengths and forms. It has 1 recall on record, none ongoing. Its official label last changed on November 12, 2026.

Medicare price 2026Brand
Pharmacies pay$165.64for 30 tablets of 5 mg tabletNo change in 4 weeks
Fair cash price
$200.99
Strengths
3
Makers
1
Updated
Nov 11

Eliquis price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
30-day starter pack Brand$5.51$407.52 / 74 tabletsNo change-43.0%
2.5 mg tablet Brand$5.51$165.37 / 30 tabletsNo change-43.1%
5 mg tablet Brand$5.52$165.64 / 30 tabletsNo change-43.0%

The lowest cost per tablet is 30-day starter pack at $5.51. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Eliquis vs generic apixaban

There is no generic version of Eliquis on the market yet. Its last listed patent or exclusivity runs to August 24, 2031 - generics often follow, though court cases and settlements can move the date either way.

GenericApixaban prices

Medicare negotiated price

$521.00$231.00-56%

Medicare negotiated a maximum fair price of $231.00 for a 30-day supply of Eliquis, against a 2023 list price of $521.00. It has applied since January 1, 2026.

What this means for patients

  • The negotiated price is what Medicare Part D plans pay for the drug - not your price at the counter.
  • What you pay depends on your plan's copay or coinsurance and where you are in the year. Coinsurance (a percentage) falls with the price; a flat copay may not change at all.
  • Out-of-pocket costs for Part D drugs are capped each year ($2,100 in 2026), whatever the drug.
  • If you don't have Medicare, the negotiated price doesn't apply to you - check the fair cash price above instead.
Every Medicare negotiated price

Supply status: shortages & recalls

No shortage reportedChecked Nov 15, 2026
No ongoing recalls1 recall on record, latest Jul 19, 2017

Recalls

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for eliquis? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedNovember 12, 2026
Version39 of 29
EffectiveAug 17, 2026
Read the label

These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.ELIQUIS® (apixaban) tablets, for oral useELIQUIS® (apixaban) tablets for oral suspensionELIQUIS® SPRINKLE (apixaban) for oral suspensionInitial U.S. Approval: 2012

This drug has a boxed warning

WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS

(B) SPINAL/EPIDURAL HEMATOMA

(A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS

Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration (2.5), Warnings and Precautions (5.1), and Clinical Studies (14.1)].

(B) SPINAL/EPIDURAL HEMATOMA

Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:

•

use of indwelling epidural catheters

•

concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants

•

a history of traumatic or repeated epidural or spinal punctures

•

a history of spinal deformity or spinal surgery

•

optimal timing between the administration of ELIQUIS and neuraxial procedures is not known

[see Warnings and Precautions (5.3)]

Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary [see Warnings and Precautions (5.3)].

Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated [see Warnings and Precautions (5.3)].

WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS

(B) SPINAL/EPIDURAL HEMATOMA

See full prescribing information for complete boxed warning.

(A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy. (2.5, 5.1, 14.1)

(B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. (5.3)

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA202155 · Bristol Myers Squibb
First approved
December 28, 2012 (14 years ago)
Latest approved change
June 24, 2026
Approved label
PDF, Jun 29, 2026
Generic makers
None on the market
Last patent listed
August 24, 2031
Exclusivity ends
October 17, 2028

Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.

Eliquis questions

How much does eliquis cost without insurance?

Pharmacies pay about $165.64 for 30 tablets of eliquis 5 mg tablet ($5.52 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $200.99. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is there a generic for Eliquis?

Yes: apixaban. Compare apixaban prices.

Is eliquis in shortage?

No shortage is reported for eliquis right now. We check the national shortage list every day.

Has eliquis been recalled?

1 recall on record, none ongoing. Recalls name specific lots - check yours.

When did the eliquis label last change?

The official label was last updated on November 12, 2026 (version 39). See what changed.

Does Medicare have a negotiated price for Eliquis?

Yes: $231.00 for a 30-day supply of Eliquis, from January 1, 2026. What you pay still depends on your plan.

Talk about eliquis

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.